Premium
Tumor markers in endometriosis
Author(s) -
Abrão M.S.,
Podgaec S.,
Pinotti J.A.,
de Oliveira R.M.
Publication year - 1999
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/s0020-7292(99)00046-6
Subject(s) - endometriosis , medicine , gastroenterology , menstrual cycle , beta 2 microglobulin , pelvic endometriosis , statistical significance , gynecology , urology , hormone
Objectives : The objective of the present study was to determine the concentrations of CA 125, CA 15‐3, CA 19‐9, carcioembryogenic antigen (CEA), alpha‐fetoprotein (AFP) and beta‐2 microglobulin (B2MG) in patients with pelvic endometriosis. Method : Fifty women were divided into two groups: group A (control) had no endometriosis or other diseases, and group B consisted of 35 women with pelvic endometriosis. All women were submitted to serum determination of CA 125, CA 15‐3, CA 19‐9, CEA, AFP and B2MG. Samples were collected during the menstrual cycle and 1 week later. Results : Mean CA 125 concentrations were altered in patients with endometriosis, but all 50 patients studied presented normal CEA, AFP and B2MG concentrations. Small variations detected in CA 19‐9 and CA 15‐3 had no statistical significance. Conclusion : CA 125 is the only important marker in the diagnosis of stages III/IV of endometriosis, especially when blood samples for its determination are obtained during the first 3 days of the menstrual cycle.